Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender

European Psychiatry

Volumn 18, Issue 8, 2003, Pages 418-420

  Morishita, Shigeru ^a   Arita, Seizaburo ^b  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Depression; Fluvoxamine; Gender; Milnacipran; Paroxetine

Indexed keywords

FLUVOXAMINE; MILNACIPRAN; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; DEPRESSION; DRUG EFFECT; DRUG RESPONSE; FEMALE; GENDER; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 0347517853     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2003.05.002     Document Type: Article

References (10)

1. Caplea A, Seachrist D, Daneshrar H, Dunphy G, Ely D. Noradrenergic content and turnover rate in kidney and heart shows gender and strain differences. J Appl Physiol 2002;92:567-71.
2. Coppen A, Whybrow PC, Noguera R, Maggs R, Prange AJ. The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine. Arch Gen Psychiatry 1972;26:234-41.
3. Halbreich U, Vital-Heme J, Goldstein S, Zandek K. Sex differences in biological factors putatively related to depression. J Affect Disord 1984;7:223-33.
4. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000;157:1445-52.
5. Morishita S, Arita S. Possible predictors of response to fluvoxamine for depression. Hum Psychopharmacol Clin Exp 2003;18:197-200.
6. Morishita S, Arita S. The clinical use of milnacipran for depression. Eur Psychiatry 2003;18:34-5.
7. Nelson JCN. Safety and tolerability of the new antidepressants. J Clin Psychiatry 1977;58(Suppl 6):26-31.
8. Old Age Depression Interest Group. How long should the elderly take antidepressant? Br J Psychiatry 1993;162:175-82.
9. Puech A, Montgomery SA, Prost JF, Prost JF, Solles A, Briley M. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 1997;12:99-108.
10. Yonkers KA, Brawman-Minter O. The pharmacologic treatment of depression: is gender a critical factor? J Clin Psychiatry 2002;63:610-5.